Literature DB >> 25027060

Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Sho Takizawa1, Tomoki Kaneyama1, Sayaka Tsugane1, Naoya Takeichi1, Satoshi Yanagisawa1, Motoki Ichikawa1, Hideo Yagita2, Byung S Kim3, Chang-Sung Koh4.   

Abstract

Programmed death-1 (PD-1) belongs to the CD28 family of co-stimulatory and co-inhibitory molecules and regulates adaptive immunity. This molecule induces the development of regulatory T cells, T cell tolerance, or apoptosis. We examined the role of PD-1 pathway in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease (TMEV-IDD) mice. Up-regulation of PD-1 and PD-1 ligand-1 (PD-L1) mRNA expression in bone marrow-derived dendritic cells were induced by TMEV infection in vitro. Furthermore, PD-1 and PD-L1 mRNA expression was increased in the spinal cords of the TMEV-infected mice in vivo. Treatment with a blocking monoclonal antibody (mAb) against PD-1, especially during the effector phase, resulted in significant deterioration of the TMEV-IDD both clinically and histologically. Flow cytometric analysis revealed a dramatically increase of CD4(+) T cells producing Th1 cytokines such as IFN-γ and TNF-α in the spinal cord of anti-PD-1 mAb-treated mice. These results indicate that the PD-1 pathway plays a pivotal regulatory role in the development of TMEV-IDD.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Demyelination; Multiple sclerosis (MS); PD-L1; Programmed Death-1 (PD-1); Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD)

Mesh:

Substances:

Year:  2014        PMID: 25027060     DOI: 10.1016/j.jneuroim.2014.06.018

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  5 in total

1.  Three immune-mediated disease models induced by Theiler's virus: Multiple sclerosis, seizures and myocarditis.

Authors:  Ikuo Tsunoda; Fumitaka Sato; Seiichi Omura; Mitsugu Fujita; Namie Sakiyama; Ah-Mee Park
Journal:  Clin Exp Neuroimmunol       Date:  2016-10-25

2.  Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.

Authors:  Marzia Anita Lucia Romeo; Marina Chiara Garassino; Lucia Moiola; Giulia Galli; Giancarlo Comi; Vittorio Martinelli; Massimo Filippi
Journal:  J Neurol       Date:  2019-10-04       Impact factor: 4.849

Review 3.  Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.

Authors:  Lidia M Yshii; Reinhard Hohlfeld; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2017-11-06       Impact factor: 42.937

Review 4.  Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis.

Authors:  Zhong-Xiang Xie; Hong-Liang Zhang; Xiu-Juan Wu; Jie Zhu; Di-Hui Ma; Tao Jin
Journal:  Mediators Inflamm       Date:  2015-01-29       Impact factor: 4.711

5.  Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.

Authors:  Vincent Pillonel; Vincent Dunet; Andreas F Hottinger; Gregoire Berthod; Luis Schiappacasse; Solange Peters; Olivier Michielin; Veronica Aedo-Lopez
Journal:  J Immunother Cancer       Date:  2019-12-02       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.